Escherichia coli Nissle 1917 (EcN) is a probiotic bacterium, commonly employed to treat certain gastrointestinal disorders. It is fast emerging as an important target for the development of therapeutic engineered bacteria, benefiting from the wealth of knowledge of E. coli biology and ease of manipulation. Bacterial synthetic biology projects commonly utilize engineered plasmid vectors, which Human rotavirus (HRV) is a leading cause of diarrhea in children. It causes significant morbidity and mortality, especially in low- and middle-income countries (LMICs), where HRV vaccine efficacy is low. The probiotic Escherichia coli Nissle (EcN) 1917 has been widely used in the treatment of enteric diseases in humans. However, repeated doses of EcN are required to achieve maximum beneficial Purpose: SYNB1891 is a live, modified strain of the probiotic Escherichia coli Nissle 1917 (EcN) engineered to produce cyclic dinucleotides under hypoxia, leading to STimulator of INterferon Genes (STING) activation in phagocytic antigen-presenting cells in tumors and activating complementary innate immune pathways. Escherichia coli Nissle 1917 (EcN) has been used as a probiotic for over a century. However, it produces the genotoxin colibactin, which has been linked to the virulence of certain E. coli strains and could promote colorectal cancer. Administering a potentially pro-carcinogenic strain as a probiotic raises public health concerns. . The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens Artur Altenhoefer et al. FEMS Immunol Med Microbiol. 2004. Free article Abstract The probiotic Escherichia coli strain Nissle 1917 (Mutaflor) of serotype O6:K5:H1 was reported to protect gnotobiotic piglets from infection with Salmonella enterica serovar Typhimurium. An important virulence property of Salmonella is invasion of host epithelial cells. Therefore, we tested for interference of E. coli strain Nissle 1917 with Salmonella invasion of INT407 cells. Simultaneous administration of E. coli strain Nissle 1917 and Salmonella resulted in up to 70% reduction of Salmonella invasion efficiency. Furthermore, invasion of Yersinia enterocolitica, Shigella flexneri, Legionella pneumophila and even of Listeria monocytogenes were inhibited by the probiotic E. coli strain Nissle 1917 without affecting the viability of the invasive bacteria. The observed inhibition of invasion was not due to the production of microcins by the Nissle 1917 strain because its isogenic microcin-negative mutant SK22D was as effective as the parent strain. Reduced invasion rates were also achieved if strain Nissle 1917 was separated from the invasive bacteria as well as from the INT407 monolayer by a membrane non-permeable for bacteria. We conclude E. coli Nissle 1917 to interfere with bacterial invasion of INT407 cells via a secreted component and not relying on direct physical contact with either the invasive bacteria or the epithelial cells. Similar articles Detection and distribution of probiotic Escherichia coli Nissle 1917 clones in swine herds in Germany. Kleta S, Steinrück H, Breves G, Duncker S, Laturnus C, Wieler LH, Schierack P. Kleta S, et al. J Appl Microbiol. 2006 Dec;101(6):1357-66. doi: J Appl Microbiol. 2006. PMID: 17105567 E. coli Nissle 1917 Affects Salmonella adhesion to porcine intestinal epithelial cells. Schierack P, Kleta S, Tedin K, Babila JT, Oswald S, Oelschlaeger TA, Hiemann R, Paetzold S, Wieler LH. Schierack P, et al. PLoS One. 2011 Feb 17;6(2):e14712. doi: PLoS One. 2011. PMID: 21379575 Free PMC article. Nonpathogenic Escherichia coli strain Nissle 1917 inhibits signal transduction in intestinal epithelial cells. Kamada N, Maeda K, Inoue N, Hisamatsu T, Okamoto S, Hong KS, Yamada T, Watanabe N, Tsuchimoto K, Ogata H, Hibi T. Kamada N, et al. Infect Immun. 2008 Jan;76(1):214-20. doi: Epub 2007 Oct 29. Infect Immun. 2008. PMID: 17967864 Free PMC article. Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. Stritzker J, Weibel S, Hill PJ, Oelschlaeger TA, Goebel W, Szalay AA. Stritzker J, et al. Int J Med Microbiol. 2007 Jun;297(3):151-62. doi: Epub 2007 Apr 19. Int J Med Microbiol. 2007. PMID: 17448724 Effect of probiotic strains on interleukin 8 production by HT29/19A cells. Lammers KM, Helwig U, Swennen E, Rizzello F, Venturi A, Caramelli E, Kamm MA, Brigidi P, Gionchetti P, Campieri M. Lammers KM, et al. Am J Gastroenterol. 2002 May;97(5):1182-6. doi: Am J Gastroenterol. 2002. PMID: 12014725 Cited by The potential utility of fecal (or intestinal) microbiota transplantation in controlling infectious diseases. Ghani R, Mullish BH, Roberts LA, Davies FJ, Marchesi JR. Ghani R, et al. Gut Microbes. 2022 Jan-Dec;14(1):2038856. doi: Gut Microbes. 2022. PMID: 35230889 Free PMC article. Review. The microbial ecology of Escherichia coli in the vertebrate gut. Foster-Nyarko E, Pallen MJ. Foster-Nyarko E, et al. FEMS Microbiol Rev. 2022 May 6;46(3):fuac008. doi: FEMS Microbiol Rev. 2022. PMID: 35134909 Free PMC article. Review. Quantifying cumulative phenotypic and genomic evidence for procedural generation of metabolic network reconstructions. Moutinho TJ Jr, Neubert BC, Jenior ML, Papin JA. Moutinho TJ Jr, et al. PLoS Comput Biol. 2022 Feb 7;18(2):e1009341. doi: eCollection 2022 Feb. PLoS Comput Biol. 2022. PMID: 35130271 Free PMC article. Efficient markerless integration of genes in the chromosome of probiotic E. coli Nissle 1917 by bacterial conjugation. Seco EM, Fernández LÁ. Seco EM, et al. Microb Biotechnol. 2022 May;15(5):1374-1391. doi: Epub 2021 Nov 9. Microb Biotechnol. 2022. PMID: 34755474 Free PMC article. Escherichia coli Nissle 1917 secondary metabolism: aryl polyene biosynthesis and phosphopantetheinyl transferase crosstalk. Jones CV, Jarboe BG, Majer HM, Ma AT, Beld J. Jones CV, et al. Appl Microbiol Biotechnol. 2021 Oct;105(20):7785-7799. doi: Epub 2021 Sep 21. Appl Microbiol Biotechnol. 2021. PMID: 34546406 Publication types MeSH terms Substances LinkOut - more resources Full Text Sources Wiley Other Literature Sources The Lens - Patent Citations Research Materials NCI CPTC Antibody Characterization Program Access through your institutionAbstractEscherichia coli strain Nissle 1917 (EcN) is a remarkable probiotic bacterium, first described by Alfred Nissle in 1916/17. As the active component of Mutaflor, EcN has been well researched over decades but detailed mechanisms by which EcN confers its probiotic effects are still elusive. EcN however, has a unique profile concerning fitness factors in the absence of any virulence factors. In several large clinical trials EcN demonstrates statistical equivalence with mesalazine in the maintenance of remission of ulcerative colitis. Also, efficacy was shown in the treatment of acute and chronic diarrhea in toddlers and children. Less convincing are the data concerning the treatment of Crohn’s disease and irritable bowel syndrome. More recently, EcN, due to its innocuous nature has been used as a delivery vehicle for vaccines, cytokines, and other substances. This chapter aims to provide an overview of clinical applications and mechanisms responsible for the observed coli Nissle 1917probioticulcerative colitisdiarrheainflammatory bowel diseasesiderophoresirritable bowel syndromeCited by (0)Copyright © 2017 Elsevier Inc. All rights reserved. Authors: Pallavi Subhraveti1, Peter Midford1, Anamika Kothari1, Ron Caspi1, Peter D Karp1 1SRI International Summary: This Pathway/Genome Database (PGDB) was generated on 8-Mar-2022 from the annotated genome of Escherichia coli Nissle 1917, as obtained from RefSeq (annotation date: 26-MAY-2021). The PGDB was created computationally by the PathoLogic component of the Pathway Tools software (version [Karp16, Karp11] using MetaCyc version [Caspi20]. It has not undergone any manual curation or review, and may contain errors. Development of this PGDB was supported by grant GM080746 from the National Institutes of Health. Sequence Source: Taxonomic Lineage: cellular organisms, Bacteria , Proteobacteria, Gammaproteobacteria, Enterobacterales, Enterobacteriaceae, Escherichia, Escherichia coli, Escherichia coli Nissle 1917 Unification Links: BIOSAMPLE:SAMN07451663, NCBI BioProject:PRJNA224116, NCBI-Taxonomy:316435 Organism or Sample Properties Environment: stool Geographic Location: Germany Freiburg Altitude (m): Collection Date: 1917 Host: Homo sapiens Annotation Provider: NCBI RefSeq Annotation Date: 2021-5-25 17:34:29 Annotation Pipeline: NCBI Prokaryotic Genome Annotation Pipeline (PGAP) Annotation Pipeline Version: Annotation Comment: Best-placed reference protein set; GeneMarkS-2+ RepliconTotal GenesProtein GenesRNA GenesPseudogenesSize (bp)NCBI Link NZ_CP0226864,8114,5381141595,055,316NCBI-RefSeq:NZ_CP022686 pNissle116140211,499NCBI-RefSeq:NZ_CP022687 pMUT287015,514NCBI-RefSeq:NZ_CP023342 Total:4,8374,5591141625,072,329 Ortholog data available?Yes Genes:4,837 Pathways:423 Enzymatic Reactions:2,300 Transport Reactions:250 Polypeptides:4,561 Protein Complexes:26 Enzymes:1,777 Transporters:708 Compounds:1,565 Transcription Units:2,883 tRNAs:86 Protein Features:6,449 GO Terms:3,793 Genetic Code Number: 11 -- Bacterial, Archaeal and Plant Plastid (same as Standard, except for alternate initiation codons) PGDB Unique ID: 2K79 References Caspi20: Caspi R, Billington R, Keseler IM, Kothari A, Krummenacker M, Midford PE, Ong WK, Paley S, Subhraveti P, Karp PD (2020). "The MetaCyc database of metabolic pathways and enzymes - a 2019 update." Nucleic Acids Res 48(D1);D445-D453. PMID: 31586394 Karp11: Karp PD, Latendresse M, Caspi R (2011). "The pathway tools pathway prediction algorithm." Stand Genomic Sci 5(3);424-9. PMID: 22675592 Karp16: Karp PD, Latendresse M, Paley SM, Krummenacker M, Ong QD, Billington R, Kothari A, Weaver D, Lee T, Subhraveti P, Spaulding A, Fulcher C, Keseler IM, Caspi R (2016). "Pathway Tools version update: software for pathway/genome informatics and systems biology." Brief Bioinform 17(5);877-90. PMID: 26454094Report Errors or Provide Feedback Page generated by Pathway Tools version (software by SRI International) on Wed Jul 27, 2022, BIOCYC17B. Engineered Escherichia coli Nissle 1917 with urate oxidase and an oxygen-recycling system for hyperuricemia treatment Rui Zhao et al. Gut Microbes. 2022 Jan-Dec. Free PMC article Abstract Hyperuricemia is the second most prevalent metabolic disease to human health after diabetes. Only a few clinical drugs are available, and most of them have serious side effects. The human body does not have urate oxidase, and uric acid is secreted via the kidney or the intestine. Reduction through kidney secretion is often the cause of hyperuricemia. We hypothesized that the intestine secretion could be enhanced when a recombinant urate-degrading bacterium was introduced into the gut. We engineered an Escherichia coli Nissle 1917 strain with a plasmid containing a gene cassette that encoded two proteins PucL and PucM for urate metabolism from Bacillus subtilis, the urate importer YgfU and catalase KatG from E. coli, and the bacterial hemoglobin Vhb from Vitreoscilla sp. The recombinant E. coli strain effectively degraded uric acid under hypoxic conditions. A new method to induce hyperuricemia in mice was developed by intravenously injecting uric acid. The engineered Escherichia coli strain significantly lowered the serum uric acid when introduced into the gut or directly injected into the blood vessel. The results support the use of urate-degrading bacteria in the gut to treat hyperuricemia. Direct injecting bacteria into blood vessels to treat metabolic diseases is proof of concept, and it has been tried to treat solid tumors. Keywords: Escherichia coli nissle 1917; catalase; hemoglobin; hyperuricemia; urate oxidase; uric acid. Conflict of interest statement No potential conflict of interest was reported by the author(s). Figures Figure 1. The schematic diagram of an engineered EcN strain for hyperuricemia was engineered to degrade UA via the pathway in Bacillus subtilis. The ygfU gene was co-expressed to facilitate UA transport, VHb was used to improve oxygen utilization, and H2O2, a byproduct of UOX, was eliminated by KatG. The new method to induce hyperuricemia in mice was established by intravenously injecting high concentrated UA. The recombinant strain was used to treat the hyperuricemia mice by oral administration or intravenous injection. Both therapies decreased UA levels of the mice. Figure 2. The optimization of UA degradation by engineering EcN cells. (a-b). UA degradation by using crude enzymes (a) or whole cells (b) of engineered EcN expressing PucLT in different plasmids under the control of different promoters. (c) UA degradation by EcN whole cells with PucL, PucLT, and PucLM. (d) UA degradation by EcN whole cells by co-expressing ygfU. The degradation curves were determined in HEPES buffer (pH = at OD600 = for whole cells or with proteins at mg/mL for enzymatic assays. The UA degradation ability of these whole cells or crude enzyme were assayed at defined time intervals. Three parallel experiments were executed to obtain averages and calculate STDEV. The one-way ANOVA method was used to calculate the p value. The Q values were calculated to get the false discovery rate (FDR). Q ‘NS’ was marked; Q ‘ns’ was marked; Q .05, ‘ns’ was marked; p .05, ‘ns’ was marked; p < .05, ‘*’ was marked; p < .01, ‘**’ was marked; p < .001, ‘***’ was marked. Similar articles Management of hyperuricemia with rasburicase review. de Bont JM, Pieters R. de Bont JM, et al. Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1431-40. doi: Nucleosides Nucleotides Nucleic Acids. 2004. PMID: 15571272 Review. Construction and expression of recombinant uricase‑expressing genetically engineered bacteria and its application in rat model of hyperuricemia. Cai L, Li Q, Deng Y, Liu X, Du W, Jiang X. Cai L, et al. Int J Mol Med. 2020 May;45(5):1488-1500. doi: Epub 2020 Feb 24. Int J Mol Med. 2020. PMID: 32323736 Free PMC article. Cloning and expression of a urate oxidase and creatinine hydrolase fusion gene in Escherichia coli. Cheng X, Liu F, Zhang Y, Jiang Y. Cheng X, et al. Ren Fail. 2013;35(2):275-8. doi: Epub 2013 Jan 9. Ren Fail. 2013. PMID: 23297748 Identification of a Formate-Dependent Uric Acid Degradation Pathway in Escherichia coli. Iwadate Y, Kato JI. Iwadate Y, et al. J Bacteriol. 2019 May 8;201(11):e00573-18. doi: Print 2019 Jun 1. J Bacteriol. 2019. PMID: 30885932 Free PMC article. Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. Bomalaski JS, Clark MA. Bomalaski JS, et al. Curr Rheumatol Rep. 2004 Jun;6(3):240-7. doi: Curr Rheumatol Rep. 2004. PMID: 15134605 Review. Cited by Effect and Potential Mechanism of Lactobacillus plantarum Q7 on Hyperuricemia in vitro and in vivo. Cao J, Bu Y, Hao H, Liu Q, Wang T, Liu Y, Yi H. Cao J, et al. Front Nutr. 2022 Jul 6;9:954545. doi: eCollection 2022. Front Nutr. 2022. PMID: 35873427 Free PMC article. References Gustafsson D, Unwin R.. The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. BMC Nephrol. 2013;14(1):164. doi: - DOI - PMC - PubMed Kang E, S-s H, Kim DK, K-h O, Joo KW, Kim YS, Lee H. Sex-specific relationship of serum uric acid with all-cause mortality in adults with normal kidney function: an observational study. J Rheumatol. 2017;44(3):380–19. doi: - DOI - PubMed Hafez RM, Abdel-Rahman TM, Naguib RM. Uric acid in plants and microorganisms: biological applications and genetics - A review. J Adv Res. 2017;8(5):475–486. doi: - DOI - PMC - PubMed Singh G, Lingala B, Mithal A. Gout and hyperuricaemia in the USA: prevalence and trends. Rheumatology. 2019;58(12):2177–2180. doi: - DOI - PubMed Shirasawa T, Ochiai H, Yoshimoto T, Nagahama S, Watanabe A, Yoshida R, Kokaze A. Cross-sectional study of associations between normal body weight with central obesity and hyperuricemia in Japan. BMC Endocr Disord. 2020;20(1):2. doi: - DOI - PMC - PubMed Publication types MeSH terms Substances Grant support This work was supported by the National High Technology Research and Development Program of China [2018YFA0901200]; the National Natural Science Foundation of China [31870085]; the National Natural Science Foundation of China [31961133015]; Qilu Youth Scholar Startup Funding of SDU. LinkOut - more resources Full Text Sources Europe PubMed Central PubMed Central Taylor & Francis Medical MedlinePlus Health Information

escherichia coli nissle 1917